An Economic Evaluation of Pharmacogenomic Testing

A more personalized approach to medicine can save lives and reduce medication-related side effects.

Pharmacogenomic (PGx) testing is a relatively recent innovation in care and has brought with it the hope of utilizing genetic information to better tailor medical interventions.

While the widespread use of PGx testing poses a significant potential benefit to the health system, our understanding of the cost-effectiveness of PGx testing is still maturing.

This whitepaper, An Economic Evaluation of Pharmacogenomic Testing, covers current knowledge surrounding PGx testing with regard to cost-effectiveness and highlights where evidence clearly supports its use.

Key Takeaways:

• The analysis of six studies performed on medicated patients
• Pharmacogenomics’ relevance to a large portion of the population
• The cost-effectiveness and even cost savings of genotype-guided strategies
• Why pharmacogenomic testing is quickly becoming a new standard of care when prescribing medication
  
  

Simply fill out the form to access the whitepaper »